BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the last patient…
BOSTON, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the last patient…
Phase 2a INFORM-MS met primary endpoint: TSPO PET microglial activation down, p=0.0168; fatigue improved in both dose arms at 12 weeks. Plus members following TLSA get this by push and email at 14:26:55 ET - it reached us 35 seconds after publication. Form 6-K main…
BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the first three…
Phase 2a INFORM-MS met dual endpoints: microglial activation down (p=0.0168) at 50 ug; MFIS fatigue down 6.17 pts (p=0.035) at 12 weeks. Plus members following TLSA get this by push and email at 07:00:06 ET - it reached us 6.9 seconds after publication. Across the 28 sessions after…
Remibrutinib reduced relapses by 31%-35% and lowered brain lesion activity Written by Michela Luciano, PhD | Nov. 3, 2026 An experimental oral MS therapy significantly reduced relapse rates and brain lesion activity compared with an approved treatment in two Phase 3 trials. (Image from iStock)…
The FDA has granted breakthrough therapy designation to enzomenib (DSP-5336) for the treatment of patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement.1 Enzomenib is an investigational, oral, small molecule inhibitor of the protein interaction between menin and lysine KMT2A, an…
For this purpose, 268 pregnant women who had high levels of RNT and mild to moderate anxiety at 16 to 28 weeks of gestation were recruited. They were randomized into two groups, with one receiving usual maternity care (UC) and another receiving the…
Originally published on cureis.com, part of the BLOX Digital Content Exchange. Food and Drug Administration advisors are discussing whether seven unapproved peptides should be allowed in certain compounded prescription drugs. CureIS Healthcare reports that smaller Medicaid plans face higher…
Presented by The Community Oncology Alliance Imperial College London’s Jadwiga A. Wedzicha, MD, discusses anti-alarmin trial results in COPD and where biologics may fit in treatment. Epithelial alarmins play an important role in driving exacerbations of chronic obstructive pulmonary disease…
Trial design, systematic reviews, medical statistics, and guideline updates.
An article joins this feed when it matches these terms. Each one is also a search of its own.